|
Digital Camera
 Hamamatsu introduces the new ORCA-Flash2.8, our first high-sensitivity digital camera based on a next-generation scientific CMOS image sensor.
...continue
Capillary Kits
Dionex Corporation has released of five new Viper capillary kits for the UltiMate 3000 intelligent LC (LCi) solutions including Tandem Operation, Automated Application Switching, on-line SPE, Parallel LC, and Automated Method Scouting.
...continue
Direct Drive Robot
 The Agilent Direct Drive Robot (DDR) from Agilent Automation Solutions has been designed for applications like drug target discovery or drug screening, where reducing cycle times means drugs traveling to market faster.
...continue
Liquid Handling Platform
 Dealing with membrane proteins in lipidic mesophases is not an easy task. Until now the sample preparation has been a very tedious and time-consuming task.
...continue
Capper/Decapper
Thermo Fisher Scientific Inc., the world leader in serving science, jointly introduced the new Capit-All IS Automated Capper/Decapper with The Automation Partnership.
...continue
|
|
More New Technologies
|
|
 Drug Discovery
Help When You Need It
 As a homeowner and aspiring gardener, I have a strong desire to go the do-it-myself route for home repair and outdoor projects. The challenge is to know my limits.
...continue
|
Genomics & Proteomics
|
Policy & Projections
Bioinsecurity
 Debate continues within the government and scientific communities over how best to balance the often-competing interests of security and research freedom when it comes to potential bioterror pathogens such as Bacillus anthracis and Botulinum neurotoxins.
...continue
|
Technology Advances
Creating Niches in Chemical Libraries
 Chemical libraries play roles in many stages of drug discovery and development. Although large pharmaceutical companies keep proprietary libraries, Big Pharma—along with biotechs and academics—can also turn to commercial libraries.
...continue
|
|
|
Divestiture of MDS Pharma Services Completed
MDS Inc., announced the completion of the divestiture of the remaining MDS Pharma Services (Discovery through Phase IIa) operations to Ricerca Biosciences LLC.
...continue
Ricerca to Acquire Early-Stage Portion of MDS Pharma
Ricerca Biosciences, LLC, announced its execution of a purchase agreement to acquire the Discovery and Preclinical business of MDS Pharma Services with facilities in Bothell, Washington; Lyon, France; and Taipei, Taiwan.
...continue
PPD Opens Research Facility in Ireland
PPD, Inc. has officially opened its contract research facility in Athlone, Ireland, which includes an 18,000-square-foot analytical testing laboratory and clinical supplies business.
...continue
|
|
More CRO News
|
|
New tools help researchers monitor and capture the reality and drama of cell biology.
Wide-field raman chemical imaging characterizes controlled-release beads.
In vivo imaging technologies provide insight into all stages of the drug development process from target identification to the optimization of clinical trials.
A wide range of molecular imaging modalities have become common in the clinic—including MRI, CT, and PET—and each of these has a miniaturized version used for small animals.
Fluorescence can be used to report the location of biomolecules or tissue of interest in vivo with a high contrast-to-background ratio. By taking a series of fluorescent images at different time points, the development of diseases can be tracked in living organisms.
A major limitation of current non-clinical imaging—especially relating to the brain—is that animals must be anesthetized. This creates a significant gap in the ability to provide serial data in diseases affecting the brain and for new and existing drugs focused on the central nervous system (CNS).
As is common in all drug discovery and development projects, upon the identification of promising lead compounds, the next steps usually involve initial safety tests in animal subjects.
BLP25 Liposome Vaccine is an investigational therapeutic cancer vaccine currently being evaluated for the treatment of unresectable, stage III non-small cell lung cancer (NSCLC) and inoperable, locally advanced, recurrent, or metastatic breast cancer.
Cilengitide is the first in a new class of investigational targeted anti-cancer therapies—called integrin inhibitors—to reach Phase 3 development.
